With great interest I read about the new insights regarding the role of type I interferon in severe COVID-19 disease. Diminished IFN-I production, inborn errors in regulation of the IFN-I response and the production of neutralizing IFN-I autoantibodies could play a role in severe COVID-19 disease in patients outside of the typical risk group.
I briefly highlighted these new findings in a breaking news item on Immunopaedia, a website promoting immunology education worldwide.